



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ashkenazi et al. Docket No.: 39780-1618P2C46  
Serial No.: 09/903,520 Group Art Unit: 1646  
Filing Date: July 11, 2001 Examiner: Andres, Janet L.  
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME**

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)

-- OR --

☐ (2) It is being filed within 3 months of entry of a national stage

-- OR --

**CERTIFICATE OF MAILING (37 CFR 1.8(a))**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: MS: No-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 7, 2003

Cheryl Ann Rogers

08/13/2003 CHNGUYEN 00000082 081641 09903520

02 FC:1806 180.00 DA

- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --  
☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and


B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fee of \$180.00 and to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-1618P2C46).

Respectfully submitted,

Dated: August 7, 2003

By:   
Ginger R. Dreger, Reg. No. 33,055

HELLER EHRMAN WHITE & MCAULIFFE LLP  
Customer No. 35489  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Tel: (650) 324-7000  
Fax: (650) 324-0638

<b>INFORMATION DISCLOSURE CITATION</b>  <b>PTO-1449</b>		ATTY. DOCKET NO. <b>39780-1618P2C46</b>		SERIAL NO. <b>09/903,520</b>			
		APPLICANT: <b>Ashkenazi, et al.</b>					
		FILING DATE: <b>07/11/01</b>		GROUP: <b>1646</b>			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<sup>6</sup> Harrison, B.D. et al., "Stimulation of Autologous Proliferative and Cytotoxic T-Cell Responses By "Leukemic Dendritic Cells" Derived From Blast Cells In Acute Myeloid Leukemia", IMMUNOBIOLOGY, 1 May 2001, Vol. 97, No. 9.							
<sup>7</sup> Fung-Leung, W. et al., "Tepoxalin, A Novel Immunomodulatory Compound Synergizes With CSA in Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection", TRANSPLANTATION, Vol. 60, No. 4, pp. 362-368, August 27, 1995.							
<sup>8</sup> Garbrecht, F.C. et al., "Lymphocyte Transformation Induced By Autologous Cells: XVIII. Impaired Autologous Mixed Lymphocyte Reaction in Subjects With AIDS-Related Complex", CLIN. EXP. IMMUNOL, Vol. 67, pp. 245-251, 1987.							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.